

NCI Division of Cancer Prevention

Research Program Focus Areas and Funding Opportunities for Investigator-initiated Research



Vikrant Sahasrabuddhe, MBBS, DrPH

Division of Cancer Prevention


vikrant.sahasrabuddhe@nih.gov

<https://prevention.cancer.gov>

Making cancer prevention possible

- HOME
- MAJOR PROGRAMS
- RESEARCH GROUPS
- CLINICAL TRIALS
- FUNDING & GRANTS
- RESOURCES
- NEWS & EVENTS
- ABOUT DCP


Research Highlights: Learning More about How Breast Cancer Progresses



This month's Research Highlights focuses on how cells progress to become breast cancer, and separately, how breast cancer may spread. Understanding these transitional moments can help researchers keep invasive cancer from spreading, and help us keep invasive cancer from spreading. One study is about mapping the structural and functional patterns inside breast tissue that distinguish between preinvasive and invasive cancer. The second report describes an increased risk of breast cancer spreading in young women diagnosed within 10 years of childbirth.

Common Chemotherapy Drugs Seem to Increase Hearing Loss in Some Adults

More than half of cancer survivors who were treated with chemotherapy for the four most common types of cancer experienced clinically significant hearing loss and tinnitus after treatment, according to new research.



In this study, more than 90% of the cancer survivors treated with platinum- or taxane-containing chemotherapies were found to have significant hearing loss and tinnitus after treatment.

MISSION STATEMENT

The Division of Cancer Prevention furthers the mission of the National Cancer Institute by leading, supporting, and promoting rigorous, innovative research and training to prevent cancer and its consequences to improve the health of all people.

[Read more about Our Research](#)

Latest News

[Read All News](#)

CP-CTNet Newsletter - September 2022

Featured Article: CP-CTNet Cross Network Study: Lynch Syndrome. Inherited susceptibility to cancer involves defects in genes that normally function...

September 30 | CP-CTNet DMACC Website

ULACNet Update - September 2022

Welcome to *ULACNet Update*, where we share programmatic and research updates for the US-Latin American-Caribbean HIV/HPV-Cancer Prevention...

September 23 | DCP News

Meetings and Events

[Review All Our Meetings and Events](#)

Statistical Adjustment for Multiplicity Virtual Workshop

Date(s):

- Wednesday, October 26, 2022 - 9:00a.m. - 3:00p.m. ET
- Thursday, October 27, 2022 - 10:00a.m. - 2:00p.m. ET

Location: Virtual


3rd International Conference on Cancer Prevention

Date(s):

- The Division of Cancer Prevention (DCP) is the extramural division of the National Cancer Institute (NCI) devoted to cancer prevention research.
- DCP conducts and supports research in cancer prevention, early detection, and screening, and on prevention and management of symptoms and toxicities in cancer patients.
- DCP leads, promotes, and supports rigorous, innovative research and training to reduce the risk, burden, and consequences of cancer for all people.

<https://prevention.cancer.gov>

DCP Leadership



<https://prevention.cancer.gov>

Cancer Biomarkers

Research to identify, develop and validate biomarkers for early cancer detection and risk assessment.



Early Detection

Research on the effectiveness and clinical impact of early detection technologies and practices.



Community Oncology and Prevention Trials

Clinical oncology trials in cancer prevention and control in community settings.



Biometry

Supports research in biostatistical, clinical trial, and epidemiological methodologies and mathematical modeling of processes relevant to cancer prevention.



Chemopreventive Agent Development

Research on cancer preventive agent development, from preclinical studies to initiation of phase I clinical trials.



Nutritional Science

Understanding how diet and food components affect cancer risk and tumor cell behavior.



Breast and Gynecologic Cancer

Prevention and early detection of breast, cervix, endometrial and ovarian cancers and their precursors.



Prostate and Urologic Cancer

Conducts and supports research on the prevention and early detection of prostate, bladder, and skin cancers.



Lung and Upper Aerodigestive Cancer

Conducts and supports research on the prevention and early detection of lung and head and neck cancers.



Gastrointestinal and Other Cancers

Prevention and early detection of colorectal, esophageal, liver, pancreas and hematolymphoid cancers.



DCP-supported preclinical, clinical, community, and symptom management research networks/programs

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

The peer-reviewed research pipeline supports new prevention interventions and biomarkers headed toward clinical trials.



Cancer Prevention Clinical Trials Network (CP-CTNet)

Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.

NCI Community Oncology Research Program (NCORP)

A clinical trials network of cancer professionals brings research to diverse populations across the country in the communities where most patients live.



Supportive Care and Symptom Management

Clinical trials and grant-funded projects examine symptoms and morbidities related to cancer and its treatment, with a focus on interventions to improve quality of life.



Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)

A collaborative research network with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)

Partnership Centers will focus on improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals.

HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network

Seeks to conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to optimize the cervical cancer screening, management, and precancer treatment cascade for WLWH.

Cancer Treatment Tolerability Consortium

A consortium of multi-disciplinary teams that is developing new methods for analyzing patient-reported outcomes in the setting of cancer clinical trials.



DCP-supported early detection and translational research networks/programs

Early Detection Research Network (EDRN)

Labs and centers bring together comprehensive infrastructure and resources critical to discovery, development and validation of biomarkers for cancer risk and early detection.



Pancreatic Cancer Detection Consortium (PCDC)

Research teams develop and test new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma and its precursor lesions.



Translational Liver Cancer (TLC) Consortium

Five Translational Research Centers conduct studies to improve surveillance of liver cancer in high-risk populations, increase detectability at early stages, and stratify at-risk patients.




Small Cell Lung Cancer (SCLC) Consortium

Six investigators conduct research to expand the understanding of the critical molecular changes in the lung that precede the development of frank SCLC and/or to identify populations at particularly high risk for SCLC.



Liquid Biopsy Consortium

A partnership with academic and industrial laboratory teams developing noninvasive liquid biopsy techniques to detect early stage cancer from biomarkers in blood, urine and sputum.




Alliance of Glycobiologists for Cancer Research

Tumor Glycomics Laboratories work to reveal cancer-related dynamics of complex carbohydrates.



Consortium for Imaging and Biomarkers (CIB)

Research Units integrate imaging strategies with biomarkers to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and diagnosis of early stage cancer.



Translational and Basic Science Research in Early Lesions (TBEL) Program

A collaborative research network that aims to further understand the biological and pathophysiological mechanisms and to facilitate biology-backed precision prevention approaches.

DCP-supported cancer screening clinical trials networks/programs



NCI Cervical Cancer 'Last Mile' Initiative

A public private partnership between several stakeholders to validate self-sampling as a comparable (non-inferior) alternative to provider-collected sampling for HPV testing in cervical cancer screening.



Multi-Cancer Detection (MCD) Research


Several assays using different technologies to detect multiple components of a growing cancer are under development for the purpose of detecting cancers at early stages.



Cancer Screening Research Network (CSRN)

The National Cancer Institute (NCI) is establishing a new Cancer Screening Research Network (CSRN) to conduct trials and studies specifically related to cancer screening.

DCP-supported research via Cancer MoonshotSM



<https://www.cancer.gov/moonshot>

<https://prevention.cancer.gov>

DCP Focus Areas for Investigator-initiated Research Studies on Cancer Prevention



Making cancer prevention possible

HOME

MAJOR PROGRAMS

RESEARCH GROUPS

CLINICAL TRIALS

FUNDING & GRANTS

RESOURCES

NEWS & EVENTS

ABOUT DCP

Funding Opportunities and Funded Grants

DCP funds and provides administrative support to clinical and laboratory researchers, community and multidisciplinary teams, and collaborative scientific networks.

Funding Opportunities

DCP funding opportunity announcements currently accepting applications.



Funded Grants

Grants awarded in the current fiscal year and carried over from prior fiscal years.



Grantsmanship Resources

For new and early-stage investigators, information relevant to preparation, submission, and tracking of grant applications, and peer review.

<https://prevention.cancer.gov>

DCP Funding Opportunities for Investigator-initiated Clinical Trials on Cancer Prevention

PAR-21-035 Cancer Prevention and Control Clinical Trials Grant Program (**R01**)

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s) National Institutes of Health (NIH)

Components of Participating Organizations National Cancer Institute (NCI)

Funding Opportunity Title **Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)**

Activity Code R01 Research Project Grant

Announcement Type Reissue of PAR-18-559

Related Notices See [Notices of Special Interest](#) associated with this funding opportunity
January 27, 2021 - Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes. See Notice [NOT-CA-21-031](#).
 • **December 11, 2020** - Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways. See Notice [NOT-CA-21-019](#).

Funding Opportunity Announcement (FOA) Number PAR-21-035

Companion Funding Opportunity [PAR-21-033](#) - National Cancer Institute's Investigator-initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Number of Applications See [Section III. 3. Additional Information on Eligibility](#).

Catalog of Federal Domestic Assistance (CFDA) Number(s) 93.393, 93.399

Funding Opportunity Purpose Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.

Project Type	<ul style="list-style-type: none"> Investigator-initiated clinical trials IND filed by investigator/institution
Submission deadlines	<ul style="list-style-type: none"> General: March, July, November (2022-23) AIDS-related: May, September, January (2022-24)
Funding caps	<ul style="list-style-type: none"> Not specified; project-specific Projects with direct costs >\$500,000/year any single year require pre-submission discussion via Awaiting Receipt of Application (ARA)

<https://grants.nih.gov/grants/guide/pa-files/par-21-035.html>

For more information, please email **Brandy Heckman-Stoddard, PhD, MPH** at heckmanbm@mail.nih.gov

<https://prevention.cancer.gov>

DCP Funding Opportunities for Investigator-initiated Clinical Trials on Cancer Prevention

PAR-22-216 NCI Clinical and Translational Exploratory/Developmental Studies (R21)

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Cancer Institute (NCI)
Funding Opportunity Title	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Activity Code	R21 Exploratory/Developmental Research Grant
Announcement Type	Reissue of PAR-20-292
Related Notices	<p>See Notices of Special Interest associated with this funding opportunity</p> <ul style="list-style-type: none">• NOT-OD-22-190 - Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022• July 21, 2022 - Notice of Correction to PAR-22-216, NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional). See Notice NOT-CA-22-108
Funding Opportunity Announcement (FOA) Number	PAR-22-216
Companion Funding Opportunity	None
Number of Applications	See Section III. 3. Additional Information on Eligibility.
Assistance Listing Number(s)	93.393, 93.394, 93.395, 93.396, 93.399
Funding Opportunity Purpose	<p>This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following new molecular agents or biologics for cancer treatment, management strategies for cancer-related symptoms or treatment-related toxicity, cancer screening or diagnostic tools, such as imaging techniques, cancer preventive agents or approaches, predictive and prognostic biomarkers for patient selection or stratification, clinically relevant <i>in vivo</i> or <i>in vitro</i> tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines), and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment</p>

Project Type	<ul style="list-style-type: none">• Applications proposing research directly related to the development of novel approaches for cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer disparities.• Investigator-initiated exploratory/pilot clinical trials; IND filed by investigator/institution
Submission deadlines	<ul style="list-style-type: none">• General: Oct/Feb/June (2022-2025)• AIDS-related: Nov/March/July (2022-2025)
Funding caps	<ul style="list-style-type: none">• \$275,000 direct costs over 2 years; \$200,000 max in one year


<https://grants.nih.gov/grants/guide/pa-files/PAR-22-216.html>

For more information, please email
Marjorie Perloff, MD at perloffm@mail.nih.gov

<https://prevention.cancer.gov>

DCP Funding Opportunities for Clinical Trials on Cancer Prevention

Cancer Prevention Clinical Trials Network (CP-CTNet)



Project Type	<ul style="list-style-type: none">• UG1/U24 Cooperative Agreement Network• IND filed by investigator/institution or NCI
Submission deadlines	<ul style="list-style-type: none">• Investigators can join UG1s led by Lead Academic Organizations (LAOs); submit concepts for approvals; approved concepts move to protocol development and conduct in CP-CTNet sites• Concept submission deadlines every quarter
Funding caps	<ul style="list-style-type: none">• Not specified; project-specific• CP-CTNet LAOs and Data Management, Auditing, and Coordinating Center (DMACC) provide clinical trials management support

<https://prevention.cancer.gov/cp-ctnet>

For more information, please email
Eva Szabo, MD at szabo@mail.nih.gov

PAR-22-173 (R34) and PAR-22-174 (U34): Cancer Prevention and Control Clinical Trials Planning Grant Program (Clinical Trials Optional)

Purpose: Facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors.

- R34 for investigator-initiated trials, U34 for trials that will be completed through an NCI-network
- Planning grant support can be requested for a maximum of 3 years.
- Application budgets are limited to \$225,000 per year and \$450,000 in direct costs over the 3-year project period without a clinical trial.
- Applications that include a pilot/feasibility clinical trial are limited to \$225,000 per year and \$600,000 in direct costs over the 3-year project period.
- Applications due: various deadlines: 2022-2025
- <https://prevention.cancer.gov/funding-and-grants/grantsmanship-resources/R34-U34-guidance>

DCP Funding Opportunities for Preclinical studies on Cancer Prevention

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel concepts are eligible to apply. PREVENT is not a grant program, but allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. PREVENT's current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

Read more [about PREVENT](#)

Application Instructions

Submitable deadlines occur twice per year on the second Monday in January and July.

NEXT Deadline: Monday, July 12, 2021

Instructions for Applicants
Please see the latest [publication template](#) (POC, 32 kb).

Supported Projects

114 Projects from PREVENT Cycles 1 through 19:

- 68 Chemoprevention projects
- 38 Immunoprevention projects
- 8 Biomarker projects

Read more about [supported projects](#) and [supported intervention approaches](#).

Available Resources

- Efficacy and Intermediate Endpoint Biomarker Work
- Technology and Pharmacology Testing
- CMRP Production of Vaccines and Biologics
- Home Concepts 2019-2023

[View available resources](#)

Program Administration


- Governance Structure
- Technology Transfer Considerations

[Learn more about program administration](#)

NATIONAL CANCER INSTITUTE

PREVENT Cancer Preclinical Drug Development Program (PREVENT) supports the best ideas in cancer prevention using NCI contract resources

The 114 projects in PREVENT involve



Preclinical Drug Development Pipeline

Discovery → 1 Proof of Concept → 2 Secondary Testing → 3 Advanced Preclinical Development → Clinical Trial

1 Proof of Concept: Synthesis, Formulation, Immunity, Efficacy, Biomarkers

2 Secondary Testing: Efficacy Reproducibility, Regimen Optimization

3 Advanced Preclinical Development: CDMO, IND-directed GMP Toxicology, Regulatory Support

114 Projects Involve: 68 Chemoprevention, 38 Immunoprevention, 8 Biomarkers

prevention.cancer.gov/PREVENT
A program of the NCI Division of Cancer Prevention

Project Type	<ul style="list-style-type: none"> IND-enabling support (proof-of-concept, secondary testing, advanced preclinical development) via NCI Research and Development Contract resources IND filed by investigator/institution or NCI
Submission deadlines	<ul style="list-style-type: none"> Submission deadlines twice-yearly: in January and July
Funding caps	<ul style="list-style-type: none"> Not specified; project-specific NCI contracts support generation of data and materials to further advance novel cancer preventive agents or biomarkers toward IND filing and proof-of-principle clinical testing.

<https://prevention.cancer.gov/prevent>

For more information, please email Shizuko Sei, MD at seis@mail.nih.gov

NIH/NCI Funding Opportunity Announcements in support of Cancer Prevention*

<i>FOA number</i>	<i>FOA title</i>	<i>FOA weblink</i>
PA-20-185	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html
PAR-20-077	National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)	http://grants.nih.gov/grants/guide/pa-files/PAR-20-077.html
PAR-21-206	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	https://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html
Various	PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])	https://grants.nih.gov/grants/guide/pa-files/PA-22-176.html https://grants.nih.gov/grants/guide/pa-files/PA-22-177.html https://grants.nih.gov/grants/guide/pa-files/PA-22-178.html https://grants.nih.gov/grants/guide/pa-files/PA-22-179.html https://sbir.cancer.gov/funding

**Not an exhaustive list; for illustrative purposes only*

Cancer Prevention Fellowship Program

Applications accepted May–August for positions starting the following June.

Be a part of the program that supports postdoctoral research and professional development, plus offers:

- Competitive stipends, relocation expenses, health insurance benefits, and travel allowances
- Support for up to four years
- Opportunity to earn your MPH, sponsored by NCI
- Research opportunities with experienced NCI mentors
- A cohort of fellows spanning STEM and other fields



cpfp.cancer.gov



CPFPCoordinator@mail.nih.gov



240-276-5626

Questions? More Information?
vikrant.sahasrabuddhe@nih.gov

<https://prevention.cancer.gov>



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol